|
ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.
|
| | | Contact Information | |
Address: |
11025 N. Torrey Pines Rd., Ste. 120
La Jolla, CA 92037
| | Phone: | 858-558-5558 | | Fax: | 858-587-4878 |
|
| Financial
Highlights | | Fiscal Year End: | March | | Revenue (2008): | 12.00 M | | Employees (2008): | 43 |
|
|
Key People
| | • |
Chairman and President:
John W. Kozarich
| | • |
VP, CFO and Director:
Yoh Ito
| | • |
Director Chemistry and Business Development:
Anna Katrin Szardenings
|
|
|
